<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03691688</url>
  </required_header>
  <id_info>
    <org_study_id>ZS-AURORA</org_study_id>
    <nct_id>NCT03691688</nct_id>
  </id_info>
  <brief_title>The Long Term Effect of Low Dose Aspirin on Uric Acid in Chinese Patients With Coronary Artery Disease（AURORA）</brief_title>
  <acronym>AURORA</acronym>
  <official_title>The Long Term Effect of Low Dose Aspirin on Uric Acid in Chinese Patients With Coronary Artery Disease（AURORA): A Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The deleterious effects of hyperuricemia (HUA) on cardiovascular disease (CVD) were well
      established. Aspirin is the most commonly prescribed antiplatelet agent for primary or
      secondary prophylaxis of CVD. Only a few short-term studies in the elderly suggested low-dose
      aspirin, e.g., 75-100 mg/day, increases serum urate by reducing urinary uric acid excretion.
      However, monitoring of renal function is currently not recommended. Little is known about the
      long-term effect of low dose aspirin on uric acid. The principal aim of this prospective
      cohort study therefore is to evaluate the renal effects of long-term aspirin (100 mg/d)
      administration in Chinese patients with coronary artery disease or other CVDs.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2018</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2021</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>24 Months</target_duration>
  <primary_outcome>
    <measure>HUA ( serum uric acid level, μmol/L)</measure>
    <time_frame>24 months after enrollment</time_frame>
    <description>Two different days of fasting uric acid &gt;420 μmol/L and women &gt;360 μmol/L under normal purine diet.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Gout attacks (ACR/EULAR classification criteria 2015)</measure>
    <time_frame>24 months after enrollment</time_frame>
    <description>Gout attacks are confirmed according to ACR/EULAR classification criteria 2015</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Initiation of UA-lowering agents</measure>
    <time_frame>24 months after enrollment</time_frame>
    <description>Starting febuxostat, allopurinol,or benzbromarone therapy at physicians` descretion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Renal impairment (serum creatine level, μmol/L)</measure>
    <time_frame>24 months after enrollment</time_frame>
    <description>2-fold elevation of serum creatine level from baseline</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Hyperuricemia</condition>
  <arm_group>
    <arm_group_label>Aspirin</arm_group_label>
    <description>Aspirin 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clopidogrel</arm_group_label>
    <description>Clopidogrel 75mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin 100 mg</intervention_name>
    <description>Aspirin 100mg will be prescribed for antiplatelet therapy at the physician`s discretion</description>
    <arm_group_label>Aspirin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel 75mg</intervention_name>
    <description>Clopidogrel will be prescribed for antiplatelet therapy in case of aspirin intolerance at the physician`s discretion</description>
    <arm_group_label>Clopidogrel</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Study population consists of angiographically diagnosised CAD patients with or without PCI,
        and patients without CAD who needs antiplatlet therapy for prophylaxis of ASCVD.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with coronary artery disease (CAD) who underwent (Percutaneous Transluminal
             Coronary Intervention) PCI therapy, documenting angiographically at least one vessel
             stenosis ≥50% among major coronary arteries (left main, left anterior descending, left
             circumflex or right coronary artery) , manifesting clinically as latent CAD, stable
             CAD, unstable CAD, and acute myocardial infarction.

          2. Patients with CAD without PCI therapy. They document angiographically at least one
             vessel stenosis ≥50% among major coronary arteries (left main, left anterior
             descending, left circumflex or right coronary artery) , and classified clinically as
             latent CAD, stable CAD, unstable CAD.

          3. Patients without CAD who needs antiplatelet therapy for prophylaxis of ASCVD,
             documenting angiographically no vessel stenosis ≥50% among any of major coronary
             arteries (left main, left anterior descending, left circumflex or right coronary
             artery).

        Exclusion Criteria:

          1. Patients with severe conditions with life expectancy less than 12 months.

          2. Patients with malignant tumor.

          3. Severe Kidney disease: patients with acute kidney injury, nephritic syndrome, renal
             replacement therapy, kidney transplant or eGFR &lt;30 mL/min/1.73 m2.

          4. Contraindicated to antiplatelet therapy because of acute bleeding.

          5. Patients who formerly administrated aspirin for at least one week or withdrawal of
             aspirin less than one month before enrollment.

          6. Patients who formerly administrated UA lowering agents at least one month before
             enrollment.

          7. Patients who formerly administrated, stopped or titrated doses of any of the following
             drugs at least one month before enrollment: losartan, irbesartan, fenofibrate,
             thiazide and loop diuretics.

          8. Patients who administrated ticagrelor as antiplatelet agent one month before
             enrollment or since then.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junbo Ge, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shalaimaiti Shali, MD</last_name>
    <phone>+86-13761553110</phone>
    <email>shali@zs-hospital.sh.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuxiang Dai, MD</last_name>
    <phone>+86-13818988550</phone>
    <email>dai.yuxiang@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Shanghai Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shalaimaiti Shali, MD</last_name>
      <phone>86+13761553110</phone>
      <email>shali@zs-hospital.sh.cn</email>
    </contact>
    <contact_backup>
      <last_name>Yuxiang Dai, MD,PhD</last_name>
      <phone>+86-13818988550</phone>
      <email>dai.yuxiang@zs-hospital.sh.cn</email>
    </contact_backup>
    <investigator>
      <last_name>Junbo Ge, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>September 28, 2018</study_first_submitted>
  <study_first_submitted_qc>September 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 2, 2018</study_first_posted>
  <last_update_submitted>November 27, 2018</last_update_submitted>
  <last_update_submitted_qc>November 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Zhongshan Hospital</investigator_affiliation>
    <investigator_full_name>Junbo Ge</investigator_full_name>
    <investigator_title>Chief of Cardiology Department</investigator_title>
  </responsible_party>
  <keyword>aspirin; coronary artery disease, uric acid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Hyperuricemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

